CEO's $2M planned sale is notable but not alarming; monitor whether the sale actually executes and at what price. Institutional accumulation suggests long-term conviction remains intact. Watch for any unexpected news or trial readouts before assuming insider pessimism, biotech CEO sales are often part of routine tax/estate planning.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $26.89entry
- T+1 · 5mo ago +2.98%α +3.11% · $27.69
- T+5 · 4mo ago +13.28%α +13.01% · $30.46
- T+20 · 4mo ago −2.01%α +0.18% · $26.35
- T+60 · 8w ago −1.12%α −3.99% · $26.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO Jon Congleton files Form 144 to sell 75,000 shares valued at ~$1.96M, sourced from RSU vestings. The planned sale is modest relative to the $2.2B market cap and his likely total holdings, but the ~$2.0M cash-out by the CEO is notable in light of Institutional 13F accumulation (8 adds, 1 new) and the lack of recent positive catalysts.
Key Facts
- Insider: Jon Congleton, CEO of Mineralys Therapeutics, filed Form 144 on 6/30/2026 to sell 75,000 shares of common stock.
- Estimated proceeds: ~$1,960,602 at filing (approx. $26.14/share based on recent trade data).
- Shares to be sold were acquired through vesting of RSU awards on 7/10/2024 (24,619 shares), 10/10/2024 (35,954 shares), and 1/10/2025 (14,427 shares).
- Congleton also received a separate RSU award of 75,000 shares on 3/31/2026 and additional shares on 4/13/2026.
- Form 144 is an advance intent to sell; the actual sale may not occur.
- Recent insider activity (30d): 3 other sells totaling $425K.
- Institutional 13F mostly supportive: 8 adds, 1 new, 4 doubled, 4 trims, 1 exit.
Financial Impact
CEO selling ~$2.0M of stock, representing about 0.09% of market cap
Risk Factors
- CEO selling ahead of potential negative catalyst not yet disclosed
- Form 144 allows sale but may not execute, uncertainty on actual timing and volume
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001964306-26-000303 |
| Document: 0001964306-26-000303-index.html | 0001964306-26-000303 |
| Document: 0001964306-26-000303.txt | 0001964306-26-000303 |
Track record
35 reports on MLYS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +20.97% at T+20 after the Jun 11, 2026 report. 5 of 10 went positive at some point.
Filters
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $15.81 Now $14.53 −8.10% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $15.24 Now $14.53 −4.66% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $15.99 Now $14.53 −9.13% settles Dec 2
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $18.18 Now $14.53 −20.08% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 6/10 Entry $21.38 Now $14.53 −32.04% settles Nov 25
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $21.10 Now $14.53 −31.14% settles Nov 18
- Oct 19, 202628d ago 8-K Neutral 2/10 Entry $21.58 Now $14.53 −32.67% settles Nov 17
- Oct 13, 20264w ago 144 Neutral 3/10 Entry $20.76 to $16.16 Now $14.53 −30.01% ▼ −22.16% −20.89% vs SPY
- Sep 30, 20266w ago 144 Neutral 3/10 Entry $23.72 to $21.24 Now $14.53 −38.74% ▼ −10.46% −11.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers